Fly News Breaks for May 20, 2019
May 20, 2019 | 16:20 EDT
Credit Suisse analyst Evan Seigerman assumed coverage of Aimmune Therapeutics (AIMT) with an Outperform rating and lowered the price target on the stock to $30 from the firm's prior $36 target, citing his belief that AR101 is likely to be approved to reduce risk from exposure in children and adults with peanut allergy. Aimmune's only competitor in peanut allergy treatment, DBV Therapeutics (DBVT), is at least a year behind in his view, Seigerman tells investors.Target $30.
News For AIMT;DBVT From the Last 2 Days
There are no results for your query AIMT;DBVT